- Home
- ATII vs TNXP Comparison
ATII vs TNXP Comparison
Compare ATII & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATII
- TNXP
- Stock Information
- Founded
- ATII 2024
- TNXP 2007
- Country
- ATII United States
- TNXP United States
- Employees
- ATII N/A
- TNXP N/A
- Industry
- ATII
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- ATII
- TNXP Health Care
- Exchange
- ATII NYSE
- TNXP Nasdaq
- Market Cap
- ATII 302.1M
- TNXP 272.0M
- IPO Year
- ATII 2025
- TNXP N/A
- Fundamental
- Price
- ATII $10.23
- TNXP $49.73
- Analyst Decision
- ATII
- TNXP Strong Buy
- Analyst Count
- ATII 0
- TNXP 2
- Target Price
- ATII N/A
- TNXP $585.00
- AVG Volume (30 Days)
- ATII 176.0
- TNXP 1.2M
- Earning Date
- ATII 01-01-0001
- TNXP 08-15-2025
- Dividend Yield
- ATII N/A
- TNXP N/A
- EPS Growth
- ATII N/A
- TNXP N/A
- EPS
- ATII N/A
- TNXP N/A
- Revenue
- ATII N/A
- TNXP $10,041,000.00
- Revenue This Year
- ATII N/A
- TNXP $22.87
- Revenue Next Year
- ATII N/A
- TNXP $711.66
- P/E Ratio
- ATII N/A
- TNXP N/A
- Revenue Growth
- ATII N/A
- TNXP N/A
- 52 Week Low
- ATII $10.01
- TNXP $6.76
- 52 Week High
- ATII $11.09
- TNXP $130.00
- Technical
- Relative Strength Index (RSI)
- ATII N/A
- TNXP 70.46
- Support Level
- ATII N/A
- TNXP $41.64
- Resistance Level
- ATII N/A
- TNXP $46.00
- Average True Range (ATR)
- ATII 0.00
- TNXP 3.70
- MACD
- ATII 0.00
- TNXP 0.38
- Stochastic Oscillator
- ATII 0.00
- TNXP 95.84
About ATII ARCHIMEDES TECH SPAC PARTNERS II CO
Archimedes Tech SPAC Partners II Co is a blank check company.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.